Mutant-Specific Oligonucleotide Probes for SARS-CoV-2 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing assays for SARS-CoV-2 detection, particularly real-time reverse transcription-PCR (rRT-PCR), suffer from laborious manual processing, long turnaround times, requirement for certified laboratories, lack of specificity, and high false-negative rates, especially when faced with SARS-CoV-2 mutants.
Innovation Solution
The development of oligonucleotides and kits that utilize specifically designed probes labeled with fluorophores and quenchers, targeting the spike gene of SARS-CoV-2, allowing for rapid and accurate discrimination between SARS-CoV-2 wildtype and its genetic variants, including probes with sequences such as SEQ ID NO:5-60, enabling PCR-based detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If real-time reverse transcription-PCR (rRT-PCR) is used for SARS-CoV-2 detection, then detection capability is achieved, but turnaround time is long and manual processing is laborious
Solution Approach 1:
The invention extracts the critical detection function from complex rRT-PCR workflows by designing specific oligonucleotide probes that directly hybridize to mutant-specific regions. This simplification removes unnecessary manual processing steps while maintaining detection capability, enabling rapid results without full PCR amplification in some embodiments.
Solution Approach 2:
The invention changes the detection parameter from general viral RNA detection to mutant-specific sequence detection by incorporating mismatched bases in probe designs. This parameter change allows differentiation between wild-type and mutant strains, providing both speed and specificity through targeted hybridization rather than comprehensive amplification.
2Reliability
If conventional assays are used for SARS-CoV-2 detection, then detection is achieved, but specificity is lacking and false-negative rates are high for mutants
Solution Approach 1:
The invention applies local quality by designing probes with specific mismatched bases at particular positions within the oligonucleotide sequence. These localized modifications create high specificity for mutant detection while maintaining overall probe stability, enabling reliable differentiation between wild-type and mutant strains through targeted sequence recognition.
Solution Approach 2:
The invention replaces the mechanical amplification and complex processing of conventional PCR with a hybridization-based detection system. This substitution uses molecular recognition principles rather than enzymatic amplification, reducing false negatives by directly detecting mutant sequences without requiring extensive sample processing that can introduce errors.
3Measurement precision
If comprehensive mutant detection is implemented, then accuracy for mutants improves, but assay complexity increases
Solution Approach 1:
The invention segments the detection task by designing separate probes for different mutant types (e.g., A23063T, G23012A, N501Y) rather than using a single complex assay. Each probe targets specific mutant regions, allowing accurate detection of multiple mutants through a series of simpler, modular tests that can be performed independently or in combination.
4Reliability
If specialized laboratories and equipment are required for detection, then detection capability is maintained, but ease of operation decreases and accessibility is reduced
Solution Approach 1:
The invention enables self-service detection by designing probes and assays that can be performed with minimal specialized equipment. The hybridization-based approach allows laboratories to conduct mutant detection using standard molecular biology techniques already available in many settings, eliminating the need for specialized facilities while maintaining reliable detection capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid, accurate, and specific detection of SARS-CoV-2 mutants and wildtype, reducing false negatives and turnaround times, suitable for point-of-care testing without the need for specialized equipment.
Implementation Method 1
contacting a sample with a) amplification primers specifically hybridizing to a target sequence... b) a mutant probe said mutant probe being a detectably labeled oligonucleotide that is able to specifically hybridize to the target sequence
Implementation Method 2
a mutant probe said mutant probe being a detectably labeled oligonucleotide... labeled with a fluorophore
Data Source
AI summary
An oligonucleotide, having a 5′ terminus and a 3′ terminus, wherein said oligonucleotide is detectably labeled and has a nucleotide sequence that consists essentially of one of the nucleotide sequences selected from SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:59 and SEQ ID NO:60.